Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06401642 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Effectiveness and Tolerability of Zavegepant for Acute Migraine Treatment Among Those Using CGRP Targeting Preventive Medications

StatusRecruiting
PhasePhase 4
Started2024-03-22
View on ClinicalTrials.gov ↗

Amendment history

2025-09-03
Study Status, Oversight v4
Re-verified, no change to tracked fields
2024-08-20
Not Yet Recruiting→Recruiting Study Status, Contacts/Locations, References v3
Trial statusNot Yet Recruiting→Recruiting
Start dateestimated 2024-07→confirmed 2024-03-22
Study sitesdetails revised at 1 of 1 site
2024-06-19
Study Status v2
Start date2024-05→2024-07
2024-05-10
Study Identification, Study Status, Eligibility v1
Eligibility criteria+111 characters
Inclusion Criteria Meets ICHDInternational Classification of Headache Disorders 3 (ICHD-3) diagnostic criteria for migraine with or without aura At le [...] 2- 8 migraine attacks per month Participants should be on a calcitonin gene-related peptide (CGRP)-targeting preventive migraine medication on a stable dose f [...] months prior to zavegepant treatment if an oral gepant or a monoclonal antibody (mAb) injected monthly, or b) at least two treatments if a mAb in [...]
Study title-21 characters
A Study to Assess Effectiveness and Tolerability of Zavegepant as anfor Acute Migraine Treatment Among Those Using CGRP Targeting Preventive Medications.
2024-05-02
Original filing
Mayo Clinic
1,015 trials monitored
See 115 trials at risk
Migraine
463 trials monitored
See 25 trials at risk
Zavegepant (Zavzpret) is approved for the acute treatment of migraine with or without aura in the US. The purpose of this study is to investigate the effectiveness and tolerability of zavegepant for the acute treatment of migraine attacks amongst participants who are using calcitonin gene-related peptide (CGRP) migraine preventive treatments.
Trial Details
NCT Number NCT06401642
Lead Sponsor Mayo Clinic
Conditions Migraine
Enrollment 200 participants
Start Date 2024-03-22
Primary Completion 2027-03 (estimated)
Study Completion 2027-03 (estimated)
Updated on ClinicalTrials.gov 2026-09-17